Targeted therapy in head and neck cancer: an update on current clinical developments in epidermal growth factor receptor-targeted therapy and immunotherapies
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - search.proquest.com
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - infona.pl
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
[引用][C] Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - cir.nii.ac.jp
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in
Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies | CiNii Research …
Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies | CiNii Research …
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, M O'Brien, M Agulnik - Drugs, 2017 - search.ebscohost.com
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - scholars.northwestern.edu
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - europepmc.org
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and …
J Moreira, A Tobias, MP O'Brien, M Agulnik - Drugs, 2017 - pubmed.ncbi.nlm.nih.gov
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. Despite this curative …
present with locally advanced disease, requiring multimodality therapy. Despite this curative …